Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Jul 25, 2019

SELL
$1.8 - $3.3 $38,523 - $70,626
-21,402 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$3.94 - $9.7 $84,323 - $207,599
21,402 New
21,402 $103,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Beirne Wealth Consulting Services, LLC Portfolio

Follow Beirne Wealth Consulting Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Beirne Wealth Consulting Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Beirne Wealth Consulting Services, LLC with notifications on news.